Description
In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.
Faculty
- Debbie Shawcross (Moderator)
- Rajiv Jalan (Faculty)
- Sara Montagnese (Faculty)
- Elliot Tapper (Faculty)
This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
Related episodes
- EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
- EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
- EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?
- EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?
ℹ️ Please click here to access the podcast version of this EASL Studio episode.